Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer.
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer. Future Oncol. 2025 Oct; 21(25):3245-3257.